Phase 3Not yet recruitingHealthspan endpoint

Fighting Osteoporosis With Risedronate Co-Therapy During Incretin (FORTIFY)

Bisphosphonate Co-Therapy to Preserve Musculoskeletal Health in Older Adults Using Tirzepatide

Sponsor
Wake Forest University Health Sciences (Academic or other)
Enrollment
96 planned
Conditions
Obesity
Interventions
Tirzepatide; Risedronate; Placebo
Ages
adults, older adults
Registry
NCT07943754

Full record on ClinicalTrials.gov

From the registry

Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.

Primary outcomes

  • Change in Hip Bone Mineral Density

History

  1. Primary completion expected

  2. Expected to start

  3. Registered

In the news